Alberta Health to Reimburse Vascepa for Cardiovascular Care

A Product Listing Agreement ("PLA") has been reached between HLS Therapeutics , a pharmaceutical company that focusses on filling gaps in the treatment of cardiovascular disease and psychiatric disorders, and the province of Alberta for the listing and public reimbursement of Vascepa (icosapent ethyl). August 1, 2024, is when the PLA with Alberta Health goes into force.

Vascepa will be compensated by Alberta Health as a Special Authority product under the terms of the PLA for the secondary prevention of cardiovascular events in patients treated with statins who have established cardiovascular disease and elevated triglycerides, such as cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularisation, or hospitalisation for unstable angina.

"The PLA with Alberta Health will significantly improve access and reimbursement for Vascepa in Canada's fourth largest province," stated Craig Millian, CEO of HLS. "Cardiovascular disease remains one of the leading causes of death in Canada1, so we are very pleased to now provide national coverage for Vascepa to more than 90% of eligible Canadians covered by both public and private plans."

Alberta is home to around 12% of all Canadians2. As previously announced, HLS has secured public funding for Veterans Affairs, Northwest Territories, Ontario, Quebec, British Columbia, Saskatchewan, New Brunswick, and the NIHB program for First Nations and Inuit peoples.